### **Overview** Poly Medicure Limited (Polymed) is a leading Indian manufacturer and exporter of disposable medical devices, with a growing global footprint and a strategic focus on innovation, vertical integration, and expansion into high-growth therapeutic areas. Established in 1997, the company has evolved from a niche vascular access provider into a diversified medtech leader with operations across 12 therapeutic segments, including cardiology, renal care, critical care, and oncology. As of November 2025, Polymed operates **15 manufacturing facilities** across **India, China, Egypt, Italy, and the UK**, with a combined annual production capacity exceeding **1.8 billion medical devices**. The company sells in **over 125 countries** and is recognized as **India’s largest exporter of plastic medical disposables**, having held this title for over a decade. --- ### **Strategic Transformation & Key Acquisitions (2025)** #### **1. Acquisition of Citieffe (Orthopedics – Oct/Sep 2025)** In September–October 2025, Polymed made a landmark strategic move by acquiring **100% of Medistream SA**, the holding company of **Citieffe SRL**, an Italy-based orthopedic medical device manufacturer specializing in **trauma and extremity fixation systems**. - **Enterprise Value:** EUR 31 million (INR 324 crores), including EUR 18.8 million equity valuation, EUR 4.2 million loan repayment, and EUR 8 million assumed debt (approx. **10x FY24 EBITDA**). - **Acquirer:** Poly Medicure B.V. (a wholly owned subsidiary). - **Key Assets:** - Vertically integrated operations: **R&D, manufacturing, marketing, and direct sales**. - Full **EU MDR and FDA approvals**, with product compliance across 25+ markets. - **45 patents**, proprietary navigation software, and strong relationships with **54+ Key Opinion Leaders (KOLs)** globally. - Manufacturing facility in **Bologna, Italy (2,100 sqm)**, operating at **60% capacity** (potential for third shift). - Direct sales presence in **Italy, USA, and Mexico**, generating **~85% of sales in target markets**. - **12% market share** in Italy and Mexico—ranked among top players. - **Performance (CY2024):** - Revenue: **EUR 17.3 million** - EBITDA: **EUR 3.1 million** (14% YoY growth) - Revenue Growth: 15% YoY - **Strategic Rationale:** - Entry into the **high-growth orthopedic space** ($61B global market, $12B trauma & extremities segment at 6–7% CAGR). - Focus on **non-elective orthopedic procedures**, ensuring demand resilience. - Expansion platform in **North America (67% of global orthopedic sales)** and Latin America. - Planned **US market expansion** via hiring sales reps and leveraging higher pricing realizations. - Synergy opportunities: **Addition of orthopedic plates** to fill product gap, **cost optimization** via partial manufacturing shift to India. - **Future Plans:** - Target **10–12% CAGR** in orthopedics; aim to **double Citieffe’s size in 5 years**. - Leverage Polymed’s **global distribution network** to expand Citieffe’s reach. - Evaluate **direct sales unit in India** and **manufacturing outsourcing to India** to improve margins. #### **2. Acquisition of PendraCare Group (Cardiology – Sep 2025)** Polymed acquired **90% of PendraCare Group** (based in Leek, Netherlands) for **€18.3 million**, with an earn-out for the remaining 10% in 2030. - **Enterprise Value:** €18.3M (EV/Revenue: 1.8x, EV/EBITDA: 13x). - **Rationale:** Strategic “bolt-on” to expand **interventional cardiology consumables** portfolio and gain access to **regulated EU and US markets**. - **Assets:** - ISO-certified facility; **CE, FDA, ANVISA, CFDA approvals**. - Product range: **Guiding and diagnostic catheters**, semi-finished components. - OEM and contract development partner to global med-tech firms. - Production capacity: **>1.5 million units/year**, currently at 700K–800K. - Sales in **35+ countries**, over 50 distributors. - **Performance (CY2024):** - Revenue: **EUR 9.9 million**, EBITDA: **EUR 1.4 million** - High gross margin: **74%** - **Synergies:** - Leverage Polymed’s R&D and manufacturing for **product development and cost optimization**. - Use PendraCare’s network to **push Polymed’s cardiology products in Europe**. --- ### **Core Business & Therapeutic Segments** | Segment | Key Highlights | |-------------------|----------------| | **Cardiology** | - Launched DES (RisoR Everolimus Eluting Stent) in Mar 2025 after CDSCO approval. <br> - Over 1,350 stents implanted by July 2025; positive clinical feedback. <br> - Launching **drug-eluting balloons, PTCA catheters, guidewires**.<br> - Clinical registry of **2,000 patients (India + Europe)** for real-world data. | | **Renal Care** | - **500–600 dialysis machines sold** in FY26; installed base >500. <br> - **First Indian company to manufacture dialyzers and dialysis machines**. <br> - Revenue: ~INR 150 Cr in FY25, projected to grow **50% YoY**. <br> - Targets **15–17% domestic market share** (from 8–9%). <br> - Supported by govt programs like **PMJAY and Ayushman Bharat** (reimbursement up to ₹1,800/session). | | **Critical Care** | - Focused on **oncology (chemotherapy delivery)** and ICU products. <br> - A top growth driver; projected **2.5x growth in FY26**. <br> - Supported by India’s plan to build **700 new oncology centers**. | | **Infusion Therapy** | - Core business; contributes **~70% of revenue**.<br> - Portfolio includes IV cannulas (top 3 global manufacturer), blood sets, dialyzers. | | **Oncology** | - Expanding via Italian subsidiary in precision drug delivery systems. <br> - Strong focus on **cancer drug delivery and safety devices**. | --- ### **Manufacturing & R&D Strength** - **Global Manufacturing Footprint:** - **15 plants** in India, China, Egypt, Italy, UK. - Key Indian facilities: **Faridabad (6), Jaipur (2), Haridwar (1)**. - Subsidiaries: **Plan1 Health (Italy), Poly Medicure Laiyang (China), Ultra for Medical (Egypt), POLYHEALTH LTD (UK)**. - **Advanced Technologies:** - Injection molding, extrusion, blow molding, **laser/ultrasonic welding**. - **AI & automation** in real-time monitoring, predictive maintenance, quality control. - Robotic arms, poka-yoke systems, vision inspection units. - **Sterilization:** - **In-house gamma sterilization plant** (300 kCi initially, scaling to 2,000 kCi) at Palwal, Haryana—**first such facility in India**. - **R&D:** - **DSIR-approved R&D center** in Faridabad. - **334+ global patents** (as of 2025); >45 new patents filed in past 2 years. - R&D spend: **~1.5% of revenue**; 5% of revenue allocated annually. - Focus areas: **Fluid management, safety devices, automation, green materials (PVC-free roadmap by 2035)**. --- ### **Global Expansion & Market Access** - **Exports:** **~70% of revenue**, diversified across Europe (~33%), India (~33%), and ROW. - **Regulatory Strength:** - Products CE, FDA, MDR, ANVISA, CFDA, and BIS certified. - Compliant with **strict EU MDR**, ahead of 2027 deadline. - **New Markets:** - **Brazil:** Wholly owned subsidiary for direct B2C model. - **USA:** Entered via FDA approvals; targeting $15–20M revenue in 3–4 years. - **UK:** Benefits from **UK-India FTA (duty elimination)**; NHS-driven opportunities. - **Distribution:** - **500+ distributors** (260+ international), many with **regional exclusivity**. - **3,000+ sales associates** globally; direct presence in Italy, USA, Mexico. --- ### **Leadership & Governance** - **Chairman & MD:** Himanshu Baid (First-generation entrepreneur) - **Joint MD:** Rishi Baid - **Executive Director:** Vishal Baid (Driving automation & manufacturing scale) - **Citieffe Leadership:** Pascal Govi (CEO, to continue post-acquisition)